Dr. Monica M. Farley is the Jonas A. Shulman Professor of Medicine and the Director of the Division of Infectious Diseases at Emory University School of Medicine and a Staff Physician at the Atlanta VA Medical Center. She is Past-President of the American Federation for Medical Research and a longstanding council member and Past-President of the Southern Society for Clinical Investigation. Dr. Farley leads a large infectious diseases division at Emory made up of nearly 90 faculty members with a large research portfolio. She serves as the academic Principal Investigator for the Georgia Emerging Infections Program (EIP), a CDC-funded surveillance network of ten national sites conducting applied epidemiologic and laboratory research focused on invasive bacterial pathogens (many vaccine preventable), influenza, foodborne diseases, healthcare-associated infections, and now COVID-19. She is a past member of the US Food and Drug Administration (FDA) Advisory Committee on Vaccines and Related Biological Products (VRBPAC) and she currently serves on the Pneumococcal Vaccine Working Group for CDC’s Advisory Committee on Immunization Practices (ACIP). She is a board member for the National Foundation for Infectious Diseases. Dr. Farley also serves as a Director of the Leadership Operations Center for the NIH-funded Infectious Diseases Clinical Research Consortium.

Daniela is a Professor of Vaccinology in the Oxford Vaccine Group, Department of Paediatrics, University of Oxford. Daniela is a global leader in Respiratory Infections and Controlled Human Infection Challenge with experience in bacterial challenge, co-infection studies, vaccine trials and mucosal immunity (nose and lungs). She leads a Programme of work on respiratory infections and vaccine development currently funded by BMGF, UKRI, NIHR and top global pharma. She leads the unique Experimental Human Pneumococcal Consortium in partnership with over 50 laboratories of worldwide experts on respiratory infection and pneumococcal biology. Her team has played a substantial role in the UK covid-19 pandemic response including being a trial site for the Phase II/III of the Oxford / Astrazeneca vaccine and heterologous prime-boost studies (COM-COV). Her research focuses mainly on: 1) Accelerate development and test novel pneumococcal vaccines using experimental carriage 2) understanding nasal and lung immune responses and correlates of protection against respiratory infections with viruses including SARS-CoV2 and bacteria 3) defining how respiratory virus co-infections (flu, RSV and SARS-CoV2) and host susceptibility (asthma, COPD, aging, smoke) alters responses to pneumococcal infection Daniela obtained a PhD in Immunology in 2009 from the University of Sao Paulo (São Paulo, Brazil). From 2001 to 2009 Daniela trained at Butantan Institute (Sao Paulo, Brazil) on development of novel vaccines against respiratory infections using different formulations, new adjuvants and routes of immunization. During her PhD Daniela was awarded the prestigious Robert Austrian Research Award in Pneumococcal Vaccinology to develop novel nasal vaccines (2006). Daniela joined the Liverpool School of Tropical Medicine in 2009 as a postdoctoral scientist and was promoted to Professor and Head of department in 2018. Twitter: danielalstm

Mark Fletcher, MD, is Senior Director, Emerging Markets Medical Affairs, Pfizer Biopharmaceuticals Group, where he serves as the Scientific Expert -- Respiratory Vaccines (Pneumococcal Adult, RSV Older Adult) and Tick-Borne Diseases (Lyme Disease) / Enteric Vaccines (C. difficile). He earned his Bachelor of Science, Chemistry (With Highest Honor) and his Doctor of Medicine degree, followed by research posts in government and in academia, and he brings nearly 30 years of vaccines industry experience in medical and scientific affairs. He is the author of more than 45 peer-reviewed articles and reviews on vaccines and vaccination.

Neil French is Professor of Infectious Diseases and Global Health, University of Liverpool, Head of Department Clinical Infection, Microbiology and Immunology, Honorary Consultant Infectious Diseases, Liverpool University Hospitals foundation trust and Director of the Wellcome funded Clinical PhD programme for Health Priorities in the Global South. He is a clinical epidemiologist and vaccinologist. He manages a multidisciplinary team of investigators spread across Liverpool and Malawi. He is best known internationally for work on pneumococcal disease in HIV infected African adults. He is a senior researcher at the Malawi Liverpool Wellcome Programme and continues to work on the topic of pneumococcal disease control as well as other vaccine interests including rotavirus, typhoid and Group B streptococcus. In the UK, he is currently taking a zika vaccine developed in Liverpool through phase 1 trials and is CI of a national UK study to diagnose and manage sepsis more effectively in the NHS (PRONTO). As well as academic activities Prof French is an active adult infectious disease physician, serves on the UK Joint Committee on Vaccines and Immunisation pneumococcal sub group and is a member of the Medicines and Healthcare Products Regulatory Agency expert working group for COVID-19 vaccines.